PMI Biopharma Solutions, Nashville Biosciences Partner on Comprehensive Drug Discovery
The strategic alliance provides an integrated product offering around drug discovery and development.
PMI Biopharma Solutions, a provider of research, pharmaceutical development, and early phase clinical manufacturing services, and Nashville Biosciences, a clinical genomic and bioinformatics company, formed a strategic collaboration in early March to leverage both parties’ expertise to provide an integrated product offering around drug discovery and development.
Under this alliance, both organizations can bundle together Nashville Bioscience’s data and in-silico technology and PMI’s laboratory services and scientific expertise to experimentally test mechanistic and therapeutic hypotheses into a comprehensive drug-target identification and validation package, the companies announced in a March 5, 2020 press release.
“With both organizations located in Nashville [TN] it was an easy decision to pair our capabilities to better serve our clients. This alliance will allow clients a smooth transition from in-silico to in-vitro studies,” remarked Dr. David Sunseri, CEO, PMI Biopharma Solutions, in the company press release.
Source: PMI Biopharma Solutions
Biotech EG 427 Raises €27 Million in Series B Funding to Advance Lead Genetic Medicine Candidate
February 24th 2025Co-led by Andera Partners and Bpifrance, the Series B financing will go toward an ongoing Phase Ib/IIa clinical study for EG 427’s lead candidate and to advance the company’s genetic medicines platform.
